ExcellGene to Manufacture SARS-CoV-2 Trimeric Omicron Spike Protein, Optimized for Subunit Vaccine, Diagnostic and Drug Development
CHO-based cGMP Process Allows for Gram Quantities of Omicron and Delta Spike Proteins
Press release
![](/wp-content/uploads/staff-maria.jpg)
Dr. Maria J. Wurm CEO, ExcellGene
![](/wp-content/uploads/staff-florian.jpg)
Dr. Florian M. Wurm CSO, ExcellGene
About ExcellGene SARS-CoV-2 trimeric spike protein products:
- All available variants, summary page
- Omicron Trimeric Spike Protein (in production)
- Delta Trimeric Spike Protein (mg/gram quantities)
- Beta Trimeric Spike Protein (mg/gram quantities)
- Alpha Trimeric Spike Protein (mg/gram quantities)
- Wuhan Trimeric Spike Protein (mg/gram quantities)
Publications on ExcellGene SARS-CoV-2 trimeric spike proteins:
- Pino et al. Trimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens. Processes 2020, 8, 1539. https://doi.org/10.3390/pr8121539
- Joel D. Allen et al., Site-specific steric control of SARS-CoV-2 spike glycosylation. Biochemistry 2021, 60, 27, 2153–2169 https://doi.org/10.1021/acs.biochem.1c00279
- Counoupas et al., Neutralizing Antibodies Against the SARS-CoC-2 Delta Variant Induced by Alhydroxyquim-ll-Adjuvanted Trimeric Spike Antigens. bioRxiv 2021.08.18.456891; https://doi.org/10.1101/2021.08.18.456891
- More at: ExcellGene SARS-CoV-2 Trimeric Spike Proteins
About ExcellGene SA
ExcellGene is a contract development and manufacturing organization (CDMO) dedicated to helping researchers and industry partners who work on vaccines, diagnostics and drug development, by making available high-quality recombinant proteins and high-yielding Chinese Hamster Ovary (CHO) cell-based manufacturing services. The Company, headquartered in Monthey, Switzerland, and its team of 55 located in 16 different countries, is celebrating 20 years of high-quality services in the development and manufacture of therapeutic and vaccine candidate biologics, from DNA to process.
Established in 2001 by Drs. Florian M. Wurm and Maria J. Wurm, as a spin-off from the Swiss Federal Institute of Technology (Lausanne, Switzerland), ExcellGene continues its core focus on innovation and exceptional attention to detail with challenging projects, such as rapid SARS-CoV-2 spike protein production. The Company has served hundreds of clients and pioneered many innovations in the use of recombinant animal cells in bioreactors, and has shared insights and know-how to advance the industry as a whole through well-known publications. ‘Expect Great Science’ is the staple principle underlying all aspects of ExcellGene’s product and customer services. See here for more information.
Point of contact
![](/wp-content/uploads/staff-sebastian.jpg)
Sebastian Rheindorf Chief Strategy Officer